The company, which aims to reach another 10 million patients in China by 2023, has invested more than 1,500 million yuan (5 million) in the past five years in research and development to support its new developments in China, said Costa Saroukos, CFO of Takeda, during a recent interview with China Daily in Shanghai.
The company posted a net profit of 287.51 million yuan (.36 million) for January-September, up 33.85 percent from one year earlier, it said in a statement to the Shanghai Stock Exchange.
The company plans to upgrade its over 300 offline direct stores for new cars and establish over 1,000 such stores in 1,000 county-level regions of China this year.
The company is also showcasing a device that integrates AI technology with traditional imaging techniques, allowing radiologists to make diagnoses through database comparisons.
The company is currently building new processing facilities in the Xinjiang Uyghur autonomous region and in Yichang of Hubei province, and upgrading a factory in Hangzhou, Zhejiang province.
The company's products are used in over 9,000 medical institutions in over 110 countries, with its total installed capacity exceeding 30,000 units, Wu said.
聊城做人流得多长时间
The company started trading on May 2 under the ticker symbol of "KXIN" after its business combination with CM Seven Star Acquisition Corporation, a Chinese blank check company formed for the purpose of entering into business ties with one or more businesses.
The company is dedicated to supporting the country's "Healthy China 2030" initiative and promoting Chinese people's health, she stressed.
The company makes it a principle to spend a lot on research and development, not cutting that budget even during the pandemic, because it recognizes the need to rapidly adapt to customers' needs and to provide higher value-added products.
The complex will cover a total area of 430,000 square meters when complete, among which 120,000 sq m will be devoted to over 300 retailers for clothing, catering, entertainment, education and sports.